- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01173055
A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia
A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia
Study Overview
Detailed Description
The objective of this study is to evaluate the effect of milnacipran on pain processing in patients with fibromyalgia and to assess the correlation between this effect and neural activation patterns during functional Magnetic Resonance Imaging (fMRI).
NOTE regarding Changes in Outcome Measures
In this Crossover Study, participants were involved for approximately 16 weeks in this sequence: a week of preparing for the initial assessments, baseline measurements (Week 0), 6 weeks on placebo or study drug followed by measurements for effect of drug or placebo (Week 6); a week of titration off of drug, if appropriate (or continued placebo, if on placebo), two weeks of washout, a new baseline assessment (Week 9), six weeks of study drug (or placebo), another set of measurements for effect of drug or placebo (Week 15), and a final titration period to maintain masking of assignment to drug or placebo. Of 17 participants who completed both sequences, data was analyzed for the 15 whose values for all measurement variables were usable.
When Outcome measure data was originally and accurately posted for baseline and change after treatment, the time frames listed were 0 and 15 weeks, because the last assessment was gathered at approximately week 15 for each person whose data is in the data set. However, given the crossover design, it seems more accurate and understandable, to show the time frame for the outcome measure as 6 because the participants were each administered drug or placebo for six weeks total. (Of course for the Placebo then Study Drug arm, the placebo data was collected at week 6, and for the Study Drug then Placebo arm, the drug data was collected at week 6, and similarly for the first group the drug data was collected at week 15 (first assignment, plus 1 week titration, 2 weeks washout, new baseline at week 9, and final collection at week 15), and for the second group the placebo data was collected at week 15.
Thus, outcome measures originally listed for 6 and 9 weeks, which were previously shown as "Data Not Reported" were effectively already included within the data presented for change from baseline shown in Week 15 in this fashion: 9 week data for the second assignment is part of the "week 0 data" for the first assignment, to get pre-treatment baseline for each treatment shown. Week 6 data is the post-treatment data which was shown as week 15, but is now recategorized as 6 week data. There is no, and never was, any data that could represent assignment to drug or placebo for 9 or 15 weeks.
Additionally, several outcome measures based on fMRI values were always listed in the protocol as other outcomes (not secondary outcomes), but had been incorrectly posted in the earlier listings on ClinicalTrials.gov. They have been accurately reclassified in the 2017 resubmission.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- University of Michigan, Chronic Pain and Fatigue Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
You may be eligible to take part in this study if the following are true:
- You are between the age of 18 and 70 years
- If you are female
- If you are right handed
- You have a diagnosis of fibromyalgia for at least 3 months, as defined by the American College of Rheumatology 1990 Criteria
- You are willing to stop taking certain medicines that you may be taking on a regular basis. The researchers will discuss these medications with you in detail
Exclusion Criteria:
You may not be eligible take part in this study if any of the following are true for you:
- You have problems with your heart or cardiovascular system
- You have problems with your liver or kidneys
- You have an autoimmune disease, or a whole-body infection like HIV or hepatitis
- You have cancer
- You are pregnant or breastfeeding
- You abuse drugs or alcohol
- You have suicidal thoughts or wishes
- You have taken milnacipran or another study drug within the last 30 days
- You have a medical problem not listed here that would make it unsafe for you to take part in the study
- The research team feels that you will be unable to complete all phases of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Milnacipran
Milnacipran will be given orally twice daily in tablet form at different times during the course of the study.
The highest dose of milnacipran to be used in the study is 200mg/day.
|
Milnacipran will be given orally twice daily in tablet form at different times during the course of the study.
The highest dose of milnacipran to be used in the study is 200mg/day.
Other Names:
|
Experimental: Placebo
Placebo will be given orally twice daily in tablet form at different times during the course of the study.
|
Placebo will be given orally twice daily in tablet form at different times during the course of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Threshold at Baseline
Time Frame: Baselines measured at week 0 and week 9 after washout from first assignment to treatment
|
The primary outcome parameter is the medium pressure pain threshold at pre-treatment baseline (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale).
Measured in kg/cm^2.
|
Baselines measured at week 0 and week 9 after washout from first assignment to treatment
|
Change in Pain Threshold From Baseline to End of Treatment.
Time Frame: baseline compared with 6 weeks of treatment
|
The primary outcome parameter is the change in medium pressure pain threshold (pressure that evokes a perceived pain intensity of 40-50 out of 100 on a numerical rating scale) from baseline to end of treatment.
Measured in kg/cm^2.
Lower values represent a worse outcome.
|
baseline compared with 6 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diffuse Noxious Inhibitory Control (DNIC) Effect at Baseline.
Time Frame: Baselines measured at week 0 and week 9 after washout from first assignment to treatment
|
0-100 numerical rating scale.
0 on the numerical scale represents a better outcome.
100 represents a worse outcome.
|
Baselines measured at week 0 and week 9 after washout from first assignment to treatment
|
Change in Diffuse Noxious Inhibitory Control (DNIC) Effect From Baseline to End of Treatment.
Time Frame: baseline compared with 6 weeks of treatment
|
0-100 numerical rating scale.
0 on the numerical scale represents a better outcome.
100 represents a worse outcome.
|
baseline compared with 6 weeks of treatment
|
Pain Tolerance at Baseline
Time Frame: Baselines measured at week 0 and week 9 after washout from first assignment to treatment
|
The primary outcome parameter is the pressure pain tolerance (maximum tolerated pressure) at pre-treatment baseline.
|
Baselines measured at week 0 and week 9 after washout from first assignment to treatment
|
Change in Pain Tolerance From Baseline to End of Treatment
Time Frame: baseline compared wtih 6 weeks of treatment
|
The primary outcome parameter is the change in pressure pain tolerance (maximum tolerated pressure) from baseline to end of treatment.
Measured in kg/cm^2.
Lower values represent a worse outcome.
|
baseline compared wtih 6 weeks of treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in fMRI Brain Activation Patterns During Pressure Stimulation From Baseline to End of Treatment
Time Frame: Baselines measured at week 0 and week 9 after washout from first assignment to treatment; treatment effect measures collected 6 weeks later
|
Baselines measured at week 0 and week 9 after washout from first assignment to treatment; treatment effect measures collected 6 weeks later
|
Change in Descending Pain Modulation From Baseline to End of Treatment (as Assessed by Changes in fMRI Brainstem Activation Patterns)
Time Frame: Baselines measured at week 0 and week 9 after washout from first assignment to treatment; treatment effect measures collected 6 weeks later
|
Baselines measured at week 0 and week 9 after washout from first assignment to treatment; treatment effect measures collected 6 weeks later
|
Change in fMRI Activation Patterns During N-back Procedure From Baseline to End of Treatment.
Time Frame: Baselines measured at week 0 and week 9 after washout from first assignment to treatment; treatment effect measures collected 6 weeks later
|
Baselines measured at week 0 and week 9 after washout from first assignment to treatment; treatment effect measures collected 6 weeks later
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Clauw, MD, University of Michigan
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Fibromyalgia
- Myofascial Pain Syndromes
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Milnacipran
- Levomilnacipran
Other Study ID Numbers
- MD-SAV-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on milnacipran
-
Indiana UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden, Denmark, Poland, United Kingdom
-
Chang Gung Memorial HospitalUnknownDepression | Ischemic StrokeTaiwan
-
California Medical Clinic for HeadacheUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraUnited States
-
Forest LaboratoriesCompleted
-
Dr. Norman HardenForest LaboratoriesCompletedChronic Pain | Knee Osteoarthritis | Degenerative Joint Disease
-
Pierre Fabre MedicamentCompletedFibromyalgia SyndromeSpain, Italy, Portugal, France, Czech Republic, Finland, Germany, Norway, Romania, Sweden
-
Valera BussellForest LaboratoriesCompleted
-
Forest LaboratoriesCypress Bioscience, Inc.Completed
-
Duke UniversityCompletedOsteoarthritis Pain | Knee Pain After Total Knee ArthroplastyUnited States